Intellia cut to Peer Perform at Wolfe Research on Nex-z safety issues

[Wall Street New York stock exchange stock market]
alexsl

Intellia Therapeutics (NTLA [https://seekingalpha.com/symbol/NTLA]) downgraded to a Peer Perform rating from Outperform at Wolfe Reseach, primarily due to emerging safety concerns tied to its Nex-z program, which have offset earlier optimism about the company’s growth trajectory.

The firm explained that these safety issues have weakened their bullish investment case, rendering the stock more vulnerable to an FDA clinical hold and dampening near-term investor sentiment.

While recent data from Intellia’s hereditary angioedema program were positive, Wolfe analysts noted that the overall risk profile has worsened, leaving limited room for further upside unless a broader biotech market rally intervenes.

Wolfe Research analysts believe Intellia faces a longer and more complicated route to commercialization, with heightened financial and regulatory challenges limiting the path to near-term stock appreciation.

MORE ON INTELLIA THERAPEUTICS

* Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4840132-intellia-therapeutics-inc-ntla-q3-2025-earnings-call-transcript]
* Intellia Therapeutics: Irreversible Edit Vs. Reversible SOCs Now A Hard Sell (Rating Downgrade) [https://seekingalpha.com/article/4836372-intellia-therapeutics-irreversible-edit-versus-reversible-socs-now-a-hard-sell-rating-downgrade]
* Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade) [https://seekingalpha.com/article/4835765-intellia-moving-to-hold-rating-in-light-of-nex-z-uncertainty-in-attr-patients]
* Cathie Wood's Ark Invest weekly moves: Adds to ACHR and CRSP, trims positions in ROKU and SOFI [https://seekingalpha.com/news/4519117-cathie-woods-ark-invest-weekly-moves-adds-to-achr-and-crsp-trims-positions-in-roku-and-sofi]
* Intellia plunges as Q3 updates indicate patient death in gene editing trial [https://seekingalpha.com/news/4518425-intellia-stock-plunges-patient-death]